Identi®cation of prostate cancers at high risk of progression is dicult and a better understanding of how peptide growth factors in¯uence cellular function might be useful. Fibroblast growth factors (FGFs) have been implicated in prostate cancer development. FGF8 was identi®ed in the Shionogi mouse mammary carcinoma SC-3 cell line as an androgen-induced mitogen. We tested if FGF8 was over-expressed in human prostate cancer and if its expression correlated with clinical data and outcome. One hundred and six cases of prostate cancer and ten cases of BPH were examined. In situ hybridization was employed to detect FGF8 mRNA expression, which was identi®ed within the malignant prostatic epithelium in 85/106 (80.2%) cases. Increased expression of FGF8 correlated signi®cantly with higher Gleason scores (P=0.0004) and advanced tumour stage (P=0.0016). Using immunohistochemistry, we con®rmed over-expression of the FGF8b isoform. Men with tumours which expressed high levels of FGF8 had worse survival (P=0.034), although FGF8 mRNA was not able to provide additional prognostic information in a multivariate analysis. Additionally, FGF8 expression was shown to persist in androgen independent prostate cancer. Using a range of normal adult tissues, FGF8 expression was restricted to neurones and the germinal epithelium in addition to the prostate. In vitro studies demonstrated that in the presence of neutralizing antibody to FGF8b there was signi®cant inhibition of prostate cancer cell growth, con®rming the biological signi®cance of FGF8 in prostate carcinogenesis.
Introduction
Prostate cancer is the second most common cause of cancer death in men in England and Wales (Oce for National Statistics, 1996) and its incidence is increasing worldwide. Although prostate cancer is common in the elderly population, more men will die with the disease than from the disease. Men who have locally advanced or metastatic disease are not amenable to curative therapy (radical surgery or radiotherapy). Androgen ablation (medical or surgical) remains the gold standard of treatment for these men and is eective in up to 70%. Unfortunately the response is only transient and the majority develop androgen resistant disease within 2 ± 3 years. Identi®cation of organcon®ned cancers at high risk of progression is difficult and a better understanding of how peptide growth factors and their receptors in¯uence cellular function might be useful. The ®broblast growth factor family consists of an increasing number of structurally related polypeptides (Mason, 1994; Smallwood et al., 1996) . FGFs interact with tyrosine kinase FGF receptors (FGFRs) and are important signalling molecules in embryogenesis and tissue dierentation, as well as being implicated in carcinogenesis including breast cancer (Yazidi and Boilly-Marer, 1995) and glioblastoma (Myers et al., 1995) . FGF8 (or androgen-induced growth factor, the eighth member of the ®broblast growth factor family) was ®rst identi®ed in the Shionogi mouse mammary carcinoma cell line SC-3 where its expression was induced by androgen (Tanaka et al., 1992) . Using tissue in situ hybridization we have previously demonstrated FGF8 mRNA expression in human prostate cancer (Leung et al., 1996) . Here we report FGF8 as the ®rst transforming peptide growth factor to have a predictive value for survival in patients with prostate cancer.
Results
We have investigated 106 cases of prostate cancer and 10 cases of benign prostatic hyperplasia (BPH). FGF8 mRNA expression was identi®ed within the malignant prostatic epithelium in 85/106 (80.2%) cases; homogeneous expression was observed in the majority of these (73/85; 85.9%). FGF8 mRNA was detected in the cytoplasm of the malignant epithelium with no stromal expression (Figure 1a) . No signals were detected by the control sense riboprobe (Figure 1b) . Immunostaining con®rmed increased expression of the FGF8b isoform in prostate cancer with immunoreactivity con®ned to the cytoplasm of malignant cells (Figure 1c ).
There was a strong correlation between the level of FGF8 mRNA expression and high Gleason scores (P=0.0004) and advanced tumour stage (P=0.0016) ( Table 1) . FGF8 mRNA expression did not relate to serum prostate speci®c antigen (PSA) levels. In 106 men followed for a median of 42 months (range 0 ± 125 months), men with tumours expressing high levels of FGF8 mRNA had signi®cantly reduced survival compared to men with tumours expressing little or no FGF8 mRNA (Figure 2 FGF8 mRNA expression in androgen independent tumours was compared to FGF8 mRNA expression in androgen dependent tumours. Androgen dependent disease was de®ned as disease in which a 75% or more decrease in the serum PSA level followed androgen ablation therapy. Androgen independent disease was de®ned as disease which failed to respond to androgen ablation, either biochemically (serum Thirty-three out of 106 (31.1%) prostate cancer specimens had adjacent benign prostatic hyperplasia (BPH); of these, 17 exhibited expression of FGF8 mRNA in a sub-population of basal cells. In 10 separate patients with BPH only, a sub-population of basal cells also showed FGF8 mRNA expression (Figure 1d ).
FGF8 expression was assessed in a range of normal adult human organs (heart, liver, kidney, lung, brain, testis and prostate) using a combination of tissue in situ hybridization and immunostaining. Only neuronal cell bodies of the brain (Figure 1e ), the germinal epithelium of the male testis (Figure 1f ) and the prostatic epithelium ( Figure 1g ) were positive for FGF8 expression.
To con®rm the functional importance of FGF8 in prostate cancer, we measured the growth response of prostate cancer cell lines incubated with neutralizing antibody to FGF8b. At a low concentration of antibody (41 mg/ml) there was inhibition of LNCaP (reduced by 25% at 0.05 mg/ml), DU145 (reduced by 32% at 0.05 mg/ml) and PC3 (reduced by 19% at 0.08 mg/ml) cell proliferation (P=0.005, 0.002, and 0.0001 respectively) relative to untreated controls (Figures 3a ± c) . However, in all three cell lines tested, this inhibitory eect was lost at higher concentrations, although in no case was there overall stimulation of cell proliferation (data not shown). Normal goat IgG, derived from pre-immune serum, was used as a control. Using the same range of concentrations as with the neutralizing antibody, these controls failed to cause any growth inhibition (data not shown).
We performed Western blotting on cytosolic lysates derived from each of the three prostate cancer cell lines, as well as SC3 cells. Using recombinant FGF8b protein as a positive control, we showed that the neutralising anti-FGF8b antibody was able to detect this isoform. However, Western blotting failed to detect FGF8b protein in any of the lysates (Figure 4 ), including SC3 (data not shown). This is consistent with previous reports which demonstrate FGF8 mRNA is detected only at low levels using RT ± PCR (Schmitt et al., 1996) . Discussion FGF8 was ®rst described as a peptide growth factor induced by androgens in SC3 cells. In vitro data suggest that FGF8 is expressed in prostate cancer cell lines (LNCaP and PC3) and that it may function as an autocrine growth factor in hormone responsive cells (Tanaka et al., 1995) . In this study we have shown that FGF8 mRNA is upregulated in human prostate cancer and that its expression correlates signi®cantly with tumour Gleason score and clinical stage. However FGF8 mRNA expression did not correlate with the hormone responsiveness of the tumours. Unexpectedly, our results also indicate that FGF8 expression persists in androgen-independent tumours. A clear relationship between FGF8 and androgen exists with FGF8 mRNA expression increasing following androgen stimulation of SC3 cells (Tanaka et al., 1992) . However, FGF8 mRNA expression has also been detected in the androgen receptor negative prostate cancer cell lines, DU145 and PC-3 (Schmitt et al., 1996; Ghosh et al., 1996) , providing further evidence of androgen-independent control of FGF8 expression. FGF8 exerts its eect by interacting with high anity FGF receptors. FGF8 binds to FGFR2-IIIc and FGFR3-IIIc (MacArthur et al., 1995a) which are expressed by the prostate gland (Leung et al., 1997; Ittman and Mansukhani, 1997) , thus forming a potential functional autocrine loop allowing androgen-independent growth.
The antisense riboprobe used in our experiments was designed to hybridize to a region common to all four potential isoforms (FGF8a, FGF8b, FGF8e and FGF8f) (Gemel et al., 1996) . By immunostaining for the FGF8b isoform, we found that FGF8b expression at protein level correlated to in situ hybridization data (Figure 1c) . It has been demonstrated that NIH3T3 cells transfected with FGF8 cDNA undergo morphological transformation to acquire a more malignant phenotype and proliferate more rapidly when injected into nude mice (MacArthur et al., 1995b) . Moreover, the NIH3T3 cells transfected with the FGF8b cDNA isoform were found to have the greatest transforming potential. These observations are consistent with our results which suggest that FGF8 mRNA upregulation is associated with clinically aggressive prostate cancer and that the FGF8b isoform is overexpressed. During the preparation of this manuscript, Tanaka et al., 1998 , reported immunohistochemically detected FGF8b protein expression in a high percentage of prostate cancers (40/43, 93%) again consistent with our ®ndings. They failed to show any correlation with tumour grade or stage, which is likely due to the small number of specimens used in their study.
Using a Cox regression model incorporating FGF8 mRNA, tumour stage and Gleason score, FGF8 mRNA was not able to provide additional prognostic information in this retrospective study although it was a predictive factor of survival in univariate analysis. We are currently assessing FGF8 as a prognostic marker in a multicentre prospective study to include a larger number of patients undergoing a randomized trial of radical prostatectomy, with full follow-up of ten years or more.
The human FGF8 gene has been mapped to chromosome 10q24 (Payson et al., 1996) , a region which has been under intense study. The PTEN/MMAC1 gene, a candidate tumour suppressor gene mapped to 10q23.3, is frequently mutated or deleted in metastatic prostate cancer (Suzuki et al., 1998) . Hence, besides the PTEN gene, the FGF8 gene from the same region of chromosome 10 is also important in the molecular pathology of prostate cancer. We have demonstrated that over-expression of FGF8 has a clinical signi®cance, and have also found no evidence of genetic deletion aecting the FGF8 gene (unpublished data).
To further substantiate the signi®cance of FGF8 in prostate cancer, we investigated the growth response of prostate cancer cell lines in vitro to a neutralizing antibody raised against FGF8b. To our knowledge, this is the ®rst published report using this antibody. Previous work has already shown that recombinant FGF8 stimulates the growth of LNCaP cells (Tanaka et al., 1995) . A signi®cant growth inhibition was clearly identi®ed in the androgen sensitive LNCaP and androgen independent DU145 and PC3 cells when exposed to a relatively low concentration of the neutralising antibody. Paradoxically, no such eect was seen at higher concentrations of the antibody. The explanation for these results is not known at present. High concentrations (up to 10 mg/ml) of antibody did not, however, result in enhanced cell proliferation compared to the untreated control cells. The observation that growth inhibition occurred at a low concentration of antibody suggests that the physiological concentration of FGF8b in prostate cancer cells in vitro is low. This is consistent with previous reports demonstrating the presence of FGF8 mRNA in prostate cancer cells by using RT ± PCR (Schmitt et al., 1996) We observed that FGF8 was expressed by a subpopulation of basal cells in the BPH specimens. This contrasts with the pattern of prostate speci®c antigen expression which is restricted to luminal cells. Indeed, in this study, there was no correlation between FGF8 mRNA expression and serum PSA levels. The pattern of FGF8 expression in BPH also contrasts with the luminal expression identi®ed in the normal prostatic epithelium, possibly suggestive of altered regulation in BPH compared to the normal prostate. Members of the FGF family including FGF8 are important in embryogenesis, particularly in limb bud development (Crossley et al., 1996) and formation of the central nervous system (Lee et al., 1997) , following which the FGFs are down-regulated. However, it is interesting to note that in our study, the only adult tissue outwith the genitourinary tract to express FGF8 mRNA was adult brain, suggesting that FGF8 is functional in adult CNS tissues. In BPH of the prostate, FGF8 expression by a sub-population (possibly the progenitor stem cells) of the basal cell compartment appears to be downregulated as amplifying or luminal cells dierentiate. This is reversed in prostate carcinogenesis and is associated with upregulation of FGF8 expression.
In conclusion, this study has demonstrated that FGF8 mRNA is expressed by a signi®cant proportion of prostate cancers and that high levels of expression correlate with Gleason score and tumour stage, as well as less favourable disease speci®c survival. Furthermore, we have demonstrated growth inhibition of prostate cancer cells in vitro, con®rming the biological importance of FGF8 in prostate cancer. In the adult, FGF8 expression is con®ned to the CNS and the male testis (in addition to the prostate), both immunologically privileged sites, making FGF8 an attractive target for novel therapeutic interventions.
Materials and methods

Patients
One hundred and six men with prostate cancer con®rmed histologically were included. The clinical details are given in Table 1 . Formalin-®xed paran-embedded specimens were obtained from transurethral resection of the prostate gland. No patients received antiandrogen therapy prior to prostate resection. The Gleason score of each individual tumour was reviewed and scored by a consultant pathologist (MCR). Three tumours could not be scored as they were primary prostatic intraductal carcinomas. A documented biochemical and clinical response to antiandrogen therapy was identi®ed in 33 men. Similarly, progressive androgen independent disease was identi®ed in 29 men; 20 of these required further resection of the prostate gland because of increasing tumour bulk causing bladder out¯ow obstruction. Antiandrogen therapy, for all patients who were commenced on such treatment, consisted of either a monthly LHRH analogue injection, or surgical removal of the androgen-secreting testicular tissue (bilateral subcapsular orchidectomy). Those patients who had, or developed, tumours that were unresponsive to antiandrogen therapy did not receive any further hormonal treatment. Ten cases of BPH obtained from transurethral resection of the prostate gland were also examined.
Normal tissues
Sections of heart, liver, kidney, lung and brain were provided from fresh post-mortem specimens. Normal prostate was derived from a male 30-year-old organ donor following ethical approval. Following formalin ®xation and embedding in paran, 5 mm sections were taken and mounted on APES coated slides for in situ hybridization.
In situ hybridization
Plasmid pGEM9Zf containing the cDNA region coding for FGF8 was kindly provided by Dr C Dickson (Viral Carcinogenesis Laboratory, ICRF, London, UK). Plasmid DNA was linearized with endonuclease digestion using HindIII and BamHI. In vitro transcription was carried out using SP6 RNA polymerase to generate the sense probe and T7 RNA polymerase to generate the antisense probe; digoxigenin-11-2' deoxyuridine 5'-triphosphate was incorporated into the riboprobes (Boehringer, UK). RNA dot blot analysis was used to quantify the amount of sense and antisense riboprobes. FGF8 mRNA expression was examined using tissue in situ hybridization as described previously (Leung et al., 1996) . 50 ml hydridization mix containing 1 ng of riboprobe was added to each section and a cover-slip was applied. Hybridization was carried out in a sealed, humidi®ed container at 528C for 18 h. A 1 : 500 dilution of alkalinephosphatase-conjugated sheep antidigoxigenin antiserum (Boehringer, UK) was incubated with the sections for 2 h to detect bound digoxigenin labelled probes. Signals were visualized by incubation with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium for 18 h in darkness. The sections were then viewed by two observers (TJD and MCR) and the intensity of the signal was graded negative, weak, moderate or strong.
Immunohistochemistry
Immunostaining was performed using a standard biotin ± avidin ± peroxidase method with a puri®ed goat polyclonal anti-FGF8b antibody (R&D Systems, Abingdon, UK) at 0.004 mg/ml. Sections were prepared in the standard manner and antigen retrieval performed by incubation in 0.1% trypsin for 18 min. Bound antibody was detected with biotinylated anti-goat immunoglobulin, and diaminobenzidine tetrahydrochloride used to generate signals. Sections incubated without any primary antibody were employed as negative controls and failed to exhibit any staining. Normal human testis was included as a positive control.
Preparation of cell lysates
Cells were harvested from monolayer cultures by trypsinization, washed with PBS and then centrifuged at 2000 r.p.m. for 10 min. Cell pellets were stored at 7708C until processed further. Lysis buer was made on ice containing 50 mM Tris (pH 7.5), 2% Triton X-100, 150 mM sodium chloride, 0.2 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluor-ide, 1 mM dithiothreotol and 25 mg/ml each of leupeptin, aprotinin and pepstatin. Each cell pellet was mixed with 1 ml lysis buer for 30 min. The cell lysates were then centrifuged at 14000 g for 3 min before the supernatants, containing the cytosolic lysate, were separated and placed in fresh tubes.
Heparin-Sepharose puri®cation
Fresh lysis buer was prepared as described above. HeparinSepharose (Pharmacia, Uppsala, Sweden) was equilibrated with lysis buer before 100 ml was added to each of the cell lysates. Samples were then incubated on a rotator wheel at 48C for 2 h. Each sample was centrifuged at 14 000 g for 5 min and supernatants discarded. The heparin-Sepharose beads were washed three times with lysis buer to remove weakly bound protein.
Western blot assay
Fifty ml heparin-Sepharose beads were added to loading buer containing b-mercaptoethanol and heated at 1008C for 5 min to eect complete reduction. Twenty-®ve ml aliquots were subjected to 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis before protein transfer to nitrocellulose membranes (Hybond-C, Amersham, UK). Blots were blocked with 5% dried milk at room temperature for 60 min. 0.2 mg/ml primary goat polyclonal antibody (anti-FGF8b, R&D Systems, Abindon, UK) was incubated with blots in sealed bags at 48C for 60 min. Blots were then incubated with the secondary antibody (conjugated to horseradish peroxidase) before visualization using ECL reagents (Amersham, UK) and autoradiography. Recombinant FGF8b protein (R&D Systems, Abingdon, UK) was used as a positive control. In addition, cytosolic lysate from SC3 cells was also subjected to Western blotting.
Proliferation assay
Three prostate cancer cell lines were used, namely LNCaP, DU145 and PC3 (American Type Culture Collection). The cells were maintained in RPMI 1640 (Life Technologies Ltd, Paisley, Strathclyde, UK) containing 10% FCS (foetal calf serum), supplemented with 100 units/ml penicillin and 100 units/ml streptomycin (Life Technologies Ltd). Subcon¯uent cells were treated with trypsin (DU145 and PC3) or 0.02% EDTA in PBS (LNCaP) and then plated at a density of 1610 4 cells/0.32 cm 2 in a 96-well plate (Corning, New York, USA). The cells were incubated with 100 ml fresh RPMI 1640 supplemented as above. After 24 h, the medium was removed and the cells were washed with PBS. 200 ml serum-free RPMI 1640 (supplemented with 100 units/ml penicillin, 100 units/ml streptomycin, 0.2 ng/ml transferrin, 0.2 ng/ml insulin and 0.5 ng/ml sodium selenite) were added to each well. After a further 24 h, this medium was replaced with 100 ml fresh medium containing a range of concentrations (0.01 ± 10 mg/ ml) of neutralizing anti-FGF8b antibody (R&D Systems).
